Tradition!

"Until recently, in vitro diagnostics were priced nearly at commodity levels and were relegated to the backwaters of the life science universe," Soren Peterson, Vivek Mittal, and Kristen Pothier write this month in In Vivo.

Lately, though, that's changed, says the trio, made up of a senior analyst, VP, and partner, respectively, of life sciences strategy consulting firm Health Advances.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

This Week in PLOS

Science Send-ups

Different Approach

Be Gone

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.